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Abstract 
 
The human antimicrobial and immunomodulatory peptide LL-37 is ubiquitously expressed and 
secreted by epithelial cells of mucosal surfaces including the gastrointestinal tract, the primary 
absorption site of orally administered drugs and food components. Besides antimicrobial 
properties, LL-37 also contributes to the pathophysiology of various diseases such as ulcerative 
colitis, Crohn’s disease and cancer. The non-covalent association of antiinflammatory drugs, 
porphyrin pigments, bile salts and food dyes to the peptide was uncovered and evaluated by 
circular dichroism (CD) spectroscopy. These agents induce the disorder-to-order conformational 
transition of the natively unstructured LL-37 leading to its helical folding. Even in the presence 
of chloride, where LL-37 is partially folded, these small molecules were able to rise the -helix 
content. CD titration data indicated positive cooperativity between the ligand molecules 
accommodated to the peptide chain resulting in multimeric complexes with apparent dissociation 
constants ranged from 2 to 500 M. Computational docking suggested the prominent role of the 
Lys8–Arg19 segment of LL-37 in the accommodation of ligand molecules, governed principally 
by salt bridges and H-bonding. Since pleiotropic biological functions of LL-37 are strongly 
conformation-dependent it could be anticipated that folding inducer compounds may modulate 
its in vivo actions and of related cationic peptides.  
 
 
 
Keywords: antiinflammatory drugs; bile acid; circular dichroism; food dyes; helical folding; 
hemin; intrinsic disorder; LL-37 
 
Abbreviations: CD, circular dichroism 
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Introduction 
Cathelicidins are an important group of animal cationic host defense peptides, the evolutionarily 
conserved components of the innate immune system [1, 2]. They are also known as antimicrobial 
peptides, since were originally described on the basis of their direct microbicidal properties. 
However, growing number of evidences refer to their immunomodulatory capacities that may 
represent the major biological function. The single human cathelicidin, the 37 amino acids long 
LL-37, with two N-terminal leucines, is rich in lysine and arginine residues and has +6 net 
charge under physiological conditions (Scheme 1). Being ubiquitously produced by epithelial 
cells and phagocytic leukocytes, it can be detected in a variety of tissues and body ﬂuids such as 
skin, airway surfaces, gastrointestinal/urogenital tract, bone marrow, blood plasma, breast milk, 
saliva and tear [3, 4]. In addition, the overexpression of LL-37 in some malignant tumors has 
recently been demonstrated [5]. Besides its broad antimicrobial activities against bacteria, fungi, 
and viral pathogens [6, 7], LL-37 also exhibits multiple pathophysiological roles including cell 
proliferation, apoptosis, angiogenesis, tissue repair, chemoattraction, and even 
carcinogenesis/metastasis [4, 8]. For instance, LL-37 possesses complex and intricate functions 
in the pathogenesis of Crohn’s disease and ulcerative colitis, the immune-mediated chronic 
inflammatory disorders of the gastrointestinal tract [9-11]. According to the current view, 
inflammatory bowel diseases are caused by a dysregulated immune response to the intestinal 
microbiota in genetically susceptible hosts. Since LL-37 is implicated in a variety of disease 
processes at diverse organ sites, it attracts increasing attention as template for the development of 
novel immunomodulatory therapeutics [12, 13]. 
As it has been shown in our previous reports, the secondary structure of cationic AMPs can 
deeply be altered by various small molecules [14, 15]. Some anionic pharmaceutical agents as 
well as endogenous metabolites (hemin, bile pigments) were able to induce disorder-to-helix 
transitions of the bee venom component melittin and its semisynthetic derivative. This structural 
transformation is analogous to the well-known, membrane binding-induced folding of LL-37 and 
other AMPs which is triggered by the anionic phospholipid head groups resulting in amphipathic 
-helices (Scheme 1) [3, 12, 16]. However, structural rearrangements of LL-37 may be 
important not only for membrane-directed antimicrobial activity but also for its specific binding 
to a variety of receptors and consequent receptor-mediated pleiotropic effects on host cells [17, 
18]. It was found by 20 years ago, that the secondary structure of LL-37 is highly sensitive to the 
presence of inorganic anions. Whereas it is unstructured in deionized water, adopts -helical 
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conformation upon addition of chloride, phosphate, sulfate or bicarbonate ions used typically at 
millimolar concentrations [12, 19]. Such a structural conversion was ascribed to the ability of 
these ions to “salt out” nonpolar residues of the peptide as well as to shield repulsive electrostatic 
forces between positively charged side chains. Taking these data and our previous observations 
into consideration, it could be assumed that the conformation of LL-37 can also be altered by 
acidic organic molecules. To test this hypothesis, circular dichroism (CD) spectroscopy was 
employed to evaluate the secondary structure of the native peptide in the presence of various 
xenobiotics and some metabolites of the human body [20-23]. The compounds used can be 
divided into the following categories: non-steroidal antiinflammatory drugs, antiallergic agents, 
suramin, TNS, food dyes, endogenous porphyrin derivatives and bile acids (Scheme 2). These 
pharmaceutical substances are widely employed in the clinical practice to treat a number of 
disorders, in the pathomechanisms of which LL-37 is involved (e.g., Crohn’s disease, ulcerative 
colitis [24], systemic lupus erythematosus [25], arthritis [26] etc.). Synthetic food colors 
commonly consumed by the human population worldwide are linked to immune-mediated 
negative behavioral eﬀects in children [27]. Porphyrin pigments and bile salts are continuously 
produced in the human body and interact with the gut microbiome and epithelial cells which 
produce LL-37. Similarly to the peptide, bile salts are also associated with the pathogenesis of 
various gastrointestinal disorders, such as inflammatory bowel diseases and colorectal cancer 
[28-30]. Furthermore, dietary heme-induced damage and consequent hyperproliferation of the 
colonic epithelial surface cells have been demonstrated emphasizing the synergistic role of the 
gut microbiota by reducing the mucus barrier function [31]. 
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Materials and Methods 
 
Materials 
Hemin, bilirubin ditaurate and stercobilin HCl (mixture of isomers) were purchased from 
Frontier Scientific. Balsalazide disodium salt dihydrate, olsalazine sodium, sulfasalazine (all 
from Santa Cruz Biotechnology), salicylic acid (Sigma-Aldrich), diclofenac sodium salt (Sigma-
Aldrich), meclofenamic acid sodium salt (MP Biomedicals), (±)-ibuprofen (Andeno B.V.), 
cromolyn sodium salt (Sigma-Aldrich), cetirizine 2HCl (AK-Scientific, Inc.), taurocholic acid 
sodium salt hydrate (Sigma- Aldrich), sodium glycocholate hydrate (Sigma-Aldrich), suramin 
sodium salt (Calbiochem), allura red AC (Sigma-Aldrich), tartrazine (Sigma-Aldrich) and  2-(p-
toluidino)-6-naphthalenesulfonic acid potassium salt (TNS, Sigma-Aldrich) were used as 
supplied. Imatinib (free base) was a gift from the Vichem Chemie Research Ltd. (Budapest, 
Hungary). All other chemicals were of analytical reagent grade. 
 
Peptide synthesis and characterization 
LL-37 amide (cat. no.: 308114, LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-NH2) 
was synthesized by NovoPro Bioscience Inc. (Shanghai, China). Peptide purity corresponded to 
96.20%. Molecular mass of the peptide (4492.25) was determined by mass spectrometry. The net 
peptide content of the supplied material was 72.12% (Shanghai Institute of Organic Chemistry, 
Chinese Academy of Sciences). 
 
Preparation of peptide and ligand stock solutions 
18 M LL-37 solution was prepared in salt-free or salted (130 mM NaCl) Tris-HCl buffer (10 
mM, pH 7.4) which was aliquoted and freezed at -20 °C. Hemin was first dissolved in 0.1 M 
NaOH and subsequently diluted by salt-free Tris-HCl buffer to obtain 0.5 mM solution. Stock 
solutions of all other compounds were made by using 10 mM salt-free Tris-HCl buffer (pH 7.4). 
 
Circular dichroism spectroscopic measurements 
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All CD spectra were measured on a JASCO J-715 spectropolarimeter at 25  0.2 C in 0.1 cm 
path-length rectangular quartz cuvette (Hellma, USA). Temperature control was provided by a 
Peltier thermostat. CD data were collected in continuous scanning mode between 190 and 260 
nm at a rate of 50 nm/min, with a step size of 0.1 nm, response time of 4 sec, three 
accumulations, and 2 nm bandwidth. CD curves of free peptide and ligand-peptide samples were 
corrected by the spectral contribution of the blank buffer solution. For CD titration 
measurements, 200 L LL-37 solution (18 M) was placed in the cuvette. After finishing the CD 
scans of the free peptide, L aliquots of ligand stock solutions were pipetted consecutively into 
the cuvette and the CD data were collected after each aliquot. 
 
Secondary structure analysis 
Deconvolutions of CD spectral sets obtained by titration of LL-37 with various compounds were 
performed with the Convex Constraint Algorithm Plus (CCA+) developed to extract base spectra 
representing common secondary structure motifs and their fractional contributions in a set of 
experimental CD curves [32, 33]. In addition to optimal basis spectra, CCA+ also yields the 
relative weights of each basis spectrum under all experimental conditions, which are indicative 
of the relative populations of each state. The analysis was performed using the CCA+ software 
with default settings and varying only the number of basis spectra. The plot of RMSD (root mean 
square deviation) versus numbers of basis spectra shows a distinct kink when three spectra were 
used, indicating this to be a significantly better fit than with two curves (Fig. S1). Using four or 
more spectra resulted in only a modest fit improvement. CCA+ analysis produced two types of 
deconvolution results (Fig. S2). Type A: one component represents the -helix CD contribution 
and two, slightly different curves are correlated with the random coil (disordered) fraction. Type 
B: random coil, -helix and -helical coiled coil spectrum. 
 
Calculation of ligand-peptide binding parameters 
Non-linear curve ﬁtting analysis of the CD titration data as well as the helical contents derived 
from the CCA+ analysis were performed by using the “One site - specific binding with Hill 
slope” equation built in the Graph Pad Prism software (ver. 6.01, San Diego, California, USA). 
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Standard deviations of the apparent Kd values and the Hill coefficients (h) are shown in the 
corresponding Tables. 
 
Computational details 
Structure of LL-37 
The helical solution NMR structure of the human LL-37 peptide (PDB entry: 2K6O) was applied  
as a rigid receptor structure for dockings [34]. Gasteiger charges were added, and the total charge 
of LL-37 was +6. 
 
Structure and parameters of the ligands 
Based on the Kd values obtained from CD spectroscopic measurements and considering the 
classification of the small molecules, the following ones were selected for docking: olsalazine, 
balsalazinde, sulfasalazine, diclofenac, meclofenamic acid, ibuprofen, glycocholate, allura red 
AC, tartrazine, TNS. The ZINC database [35] was used to obtain the 3D structures (olsalazine: 
ZINC3812865; balsalazide: ZINC3952881; sulfasalazine: ZINC3831490; diclofenac: 
ZINC1281; meclofenamic acid: ZINC1655; ibuprofen: ZINC2647; glycocholate: ZINC8143774; 
allura red AC: ZINC100048689; TNS: ZINC2168595). In cases where multiple structures were 
provided within one database entry, that one which corresponds to pH 7.4 was selected. 
However, the 3D structure of tartrazine provided by ZINC database (ZINC100048501) differs 
from that reported in the literature at pH close to physiological conditions [36]. Thus, the 
structure relevant in these conditions was parameterized applying the same methodology as of 
molecules presented in ZINC database [37]: the 3D structure was created and optimized using 
MarvinSketch (ver. 18.13.0, Chemaxon, 2018) and the partial charges was calculated using 
AMSOL (ver. 7.1, University of Minnesota, Minneapolis, 2004). 
 
Docking procedure 
Dockings of the flexible ligands onto the rigid receptor were carried out by Autodock 4.2 [38] 
applying the following parameters. The box grid size was chosen to contain (127×127×127) grid 
points with a spacing of 0.497 Å. The number of individuals in the population was set to 300 
using a maximum of 105 generations and 9,995 × 10
5
 energy evaluations per docking. Further 
parameters were chosen to be default and the Lamarckian genetic algorithm was applied to carry 
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out the dockings. The initial position and conformation of the ligand was random and in sum, 
1,000 docking/ligand were performed on LL-37. 
 
Clustering 
Hierarchical agglomerative clustering (bottom-up) procedure was applied on all ligands, using 
AmberTools ver. 16 cpptraj package [39]. The finishing criteria of minimum distance between 
clusters () was set to 5 Å and the number of remaining clusters (n) were chosen to be 5. RMSD 
of all atoms were used as distance metric without fitting the structures before calculating the 
RMSD. The three most populated clusters were chosen for further analysis. The structure in each 
cluster that has the lowest cumulative distance to every other point was considered as a 
representative. 
Molecular surface calculation was carried out on all docking of each ligand using the cpptraj 
molsurf command and the averages were used as representative values.  
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Results and Discussion 
 
CD spectroscopic evaluation of the impact of small molecules on the secondary structure of LL-
37 
The far-UV CD spectrum of LL-37 obtained in salt-free Tris-HCl buffer at pH 7.4 is dominated 
by a negative peak of -* origin centered around 202 nm whereas the n-* transitions of the 
amide chromophores generate a less intense, broad band displaying a minimum at 225 nm (Fig. 
1). In line with previous experimental data, this CD signature is characteristic to the unstructured 
conformation of LL-37 [19, 40]. To study the effect of various small molecules on the secondary 
structure of the peptide, CD titration experiments were conducted. Stepwise addition of the guest 
compounds resulted in dramatic spectral changes (Fig. 1). At the very first phase of the titration, 
the amplitude of the main negative band decreased and its minimum was shifted to about 205 
nm. Upon further addition of the ligands, the peak gained intensity and exhibited more red shift 
(~209 nm). Concomitantly, a positive band was developed in the short-wavelength region 
showing a max around 193-195 nm and the magnitude of the n-
*
 CD band above 215 nm 
enhanced gradually (Fig. 1). In relation to the free-form of LL-37 that adopts an essentially 
random coil conformation, the transformed CD curves exhibited distinct double minima (~223-
226 and ~209 nm), a zero intercept around 201 nm and a single positive maximum below 200 
nm (~193 nm). Such a spectral pattern is consistent with those observed for canonical -helices 
implying that in a different extent these compounds are able to provoke the disorder-to-helix 
transition of LL-37. It is to be noted that the titration curves displayed an isodichroic point 
around 205 nm signifying that the folding occurs via a dynamic equilibrium between the 
disordered and the helical species. These conclusions are fully consonant with the deconvolution 
of the CD spectra showing the progressive increase of the -helix content (Fig. 2). The most 
effective drugs which produced the greatest helical transformation (~70% or higher) belong to 
the antiinflammatory group. The monoacid diclofenac/meclofenamic acid and the dicarboxylic 
olsalazine/balsalazide resulted in similar CD spectroscopic changes both in quanti- and 
qualitative terms whereas other NSAIDs triggered a weaker (sulfasalazine, ibuprofen) or only a 
mild (salicylic acid) structural rearrangement. Despite of the presence of acidic functions and 
aromatic moieties, the antiallergic cromolyn and cetirizine (Scheme 1) showed only a limited 
helix-inducing ability which points out some structure-folding inducing activity relationships. 
The food color tartrazine and allura red AC increased abruptly the helix content that reached a 
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maximum at around 1:1 dye:peptide molar ratio. In this sense, only the antiprotozoal drug 
suramin was more effective producing a ~70% -helix fraction at lower ligand loading of the 
peptide chain (Fig. 2, Fig. 3). In relation to the other compounds tested in this work, the highest 
number of the acidic (sulfate) groups in suramin may decisively contribute to its superior folding 
activity. Interestingly, tartrazine and allura red AC have recently been reported to induce 
amyloid transformation of serum albumins and -lactoglobulin under acidic condition (pH 3.5). 
The formation of cross -sheet structured fibrils were attributed to electrostatic and hydrophobic 
dye-protein residue interactions [41-43]. 
Hemin and its water soluble metabolite bilirubin ditaurate also displayed strong structure 
ordering effect. In contrast, the bilirubin derivative pigment stercobilin formed via enzymatic 
reduction by intestinal bacteria proved to be a much weaker inducer. Similarly, addition of the 
bile salt glyco- and taurocholate resulted in appreciable conformational changes only at large 
molar excess. As amphipathic molecules constituted from hydrophobic and hydrophilic regions, 
these steroid acids readily form micelles in aqueous solution [44]. In analogy with lipid 
membranes, the apolar interior of such particles may promote the helical folding of unstructured 
peptide sequences. However, the lowest critical micelle concentration of these bile salts (~9 mM 
for glycocholate [45] and 3-5 mM for taurocholate [46]) is much higher than the concentrations 
at which the folding of LL-37 was detected (<0.4 mM, Fig. 2). 
Based on the relative concentrations of the ligands at which the largest helical fraction was 
obtained, they can be categorized into three groups (Fig. 3). Strong inducers including suramin, 
food dyes, hemin, bilirubin, olsalazine, etc. display their maximal folding effect below 70 M. 
Diclofenac, balsalazide, cromolyn, TNS and stercobilin belong to the medium category with cc. 
values in the 100-200 M range. Finally, bile salts and ibuprofen can be classified as weak 
inducers being most effective above 300 M. Comparison of these groups shows that similar 
conformation-ordering effect is associated to chemically diverse molecules, e.g. hemin-
olsalazine, meclofenamic acid-bilirubin ditaurate. And vice versa, structurally related compounds 
such as stercobilin-hemin, stercobilin-bilirubin ditaurate and diclofenac-meclofenamic acid own 
considerably different helix-inducing power. Accordingly, it seems that distinct chemical motifs 
could exert equivalent ordering effects but even relatively small structural modifications may 
result in a great impairment in the folding efficiency. 
It is to be noted that the N-arylaminonaphthalene sulfonate derivative TNS also exhibited a 
significant structure-ordering effect (Fig. S3). This compound and related naphthalene sulfonate 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
9 
 
derivatives (ANS, bis-ANS, bis-TNS) are widely employed as non-covalent fluorescent probes 
for conformational studies of peptides/proteins [47, 48] or the mechanisms and kinetics of 
amyloid formation [49]. In this respect, the helix-promoting feature of TNS demonstrated herein 
implies that this molecule (and likely its congeners) may act not only as a passive reporter but 
can directly change the secondary structure of target sequences rich in cationic residues. 
In order to test whether ligand-side chain hydrophobic interactions alone are capable to induce 
helical folding, the tyrosine kinase inhibitor drug imatinib having multiple aromatic rings but no 
anionic groups was used. Addition of the drug to LL-37 caused only a moderate intensity 
reduction of the main CD band and left the n-* region unaltered (Fig. S4). 
 
Calculation of ligand-peptide binding parameters 
The increase of the -helical content (%) of LL-37 obtained from the analysis of the CD spectra 
were plotted against the concentrations of the inducers applied during the titrations. Non-linear 
regression analysis of these data points yielded the apparent dissociation constant (Kd) and the 
Hill coefﬁcient (Fig. S3). The values calculated by this way are in a good correlation with those 
derived from the non-linear regression analysis of the CD extremum of the n-* band measured 
around 223-226 nm (Table 1). According to the h values found greater than one for all 
compounds, there is a positive binding cooperativity between the ligand molecules bound to 
multiple sites along the peptide chain, i.e.  accommodation of the first molecule enhances the 
binding of the second one. Suramin exhibited the greatest binding affinity (2 M) followed by 
food colors, bilirubin ditaurate, olsalazine and hemin. NSAIDs and TNS bind to LL-37 less 
avidly whereas the affinity of ibuprofen, cromolyn and bile salts is lower by an order of 
magnitude (Table 1). 
 
Effect of chloride on the ligand induced folding of LL-37 
Chloride is the major anion in the extracellular fluid compartments including blood plasma and 
interstitial fluids (95-110 mM). In addition, it is the most significant component of airway 
surface liquid (120-125 mM) as well as gastric and intestinal juices [50, 51]. As previous 
experiments demonstrated, addition of chloride or other inorganic anions provoke the disorder-
to-helix transition of LL-37 [19]. Therefore, Tris-HCl buffer solution of LL-37 was titrated with 
NaCl to determine the extent of -helicity at rising chloride concentrations (Fig. S5). As the 
sigmoidal shape of the titration curve demonstrates, chloride ions from ~50 mM cooperatively 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
10 
 
promote the helical transformation of the peptide resulting in a maximal helical content (~80%) 
above 300 mM. However, the helix fraction is only ~25-35% around physiological Cl
-
 levels 
(100-130 mM). Therefore, the conformational effect of some efficient helix promoters was tested 
on LL-37 dissolved in 10 mM Tris-HCl buffer solution containing 130 mM sodium chloride. In 
most instances, addition of the ligands produced intensity increase both of the n-* and -* CD 
bands at 224 and 208 nm, respectively, and the development of a positive CD feature below 200 
nm (Fig. 4). These changes associated with the red shift of the -* peak enhance the helical 
feature of the spectrum suggesting the rise of the helix content and thus the preserved fold-
inducing activity of the molecules at a chloride level characteristic to in vivo conditions. In 
relation to the Kd values estimated at 10 mM chloride (Table 1), the LL-37 binding of olsalazine 
and diclofenac did not change significantly, whereas balsalazide, meclofenamic acid and 
tartrazine exhibited weaker affinity (Table 2). Using of hemin, bilirubin ditaurate and suramin 
resulted in the progressive increase of the CD222/CD208 ratio indicating the peptide aggregation 
promoting effect of these agents at higher chloride concentration (Fig. S6). 
 
Computational studies 
To reveal potential binding poses and gain a molecular level insight on the atomistic interactions 
between LL-37 and different classes of molecules, some of them were docked 1,000 times to the 
helical form LL-37 [34] followed by the clustering of the docked structures. Table 3 shows the 
molecular properties, binding affinities and clustering results of the selected compounds. The 
evaluation of the binding free energies indicated positive binding affinity towards LL-37, which 
is in line with the experimental data. The absolute values of the calculated dissociation constants 
(   
    ) differs in average by one order of magnitude compared to those derived from the 
spectroscopic experiments, which is expected considering the drawbacks of rigid receptor-
flexible ligand docking and the diverse chemical nature of the molecules under study [52, 53]. 
The relative rankings of the Kd values are in a good coincidence with those obtained 
experimentally (Fig. 5). The only exception is the antiinflammatory drug ibuprofen, which 
exhibited opposite ranks compared to the experimental results (see the corresponding 
Spearman’s correlation coefficients in Table S1 and S2). This may be related to the considerably 
different approaches used to estimate the binding affinities. Kd obtained from CD experiments is 
associated with the helical folding ability of the ligands which is mediated by dynamic, 
multimolecular interactions with the peptide chain. In contrast, the calculated binding free 
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energies stem from the consideration of various physicochemical interactions found between the 
ligand and the helical peptide. It also needs to be stressed, that the semi-empirical Autodock4 
force field was calibrated on ligand-protein complexes [38] instead of the much more flexible 
peptides, whereas conformational freedom, protonation state and charge distribution of the 
ligands can potentially affect the docking results [52, 54]. Furthermore, the calculated binding 
free energies and dissociation constants are the averages of different docking poses as we had no 
structural information about the preferred binding sites. As a result, the energies and dissociation 
constants might be correlated with the number of different binding poses (which is represented in 
our study by the total number of clusters as clustering was applied to differentiate between 
different docking poses) and the surface area of the molecules; see Table S1). 
To reveal the potential binding sites, the docked structures were clustered (see Computational 
details). The three most populated clusters of each ligand were analyzed (Table 3). In the 
majority of the cases, the most populated cluster was also energetically the most favoured. 
Exceptions are the clusters of olsalazine and TNS of which the first cluster showed no significant 
binding energy difference with at least one of the clusters. In addition, the second cluster of 
ibuprofen has slightly, but significantly better binding energy with almost same population size. 
Based on these findings, the representatives of the first cluster of each compound was considered 
as typical binding site, except for ibuprofen where the representative structure of the second 
cluster was used as characteristic binding pose. Accordingly, tartrazine (Fig. 6), sulfasalazine 
(Fig. S7) and balsalazide (Fig. S8) bind preferably to the same, lysine-rich segment of LL-37 
which could be a consequence of the structural and charge-related similarities they share. Salt 
bridges between the negatively charged carboxylate or sulfonate groups and the adjacent basic 
residues (Lys12, Lys15, Lys10 or Lys18) are characteristic for these compounds. Olsalazine is in 
a slightly different position, but still occupies the same site, as it binds to Lys10 and Lys18 with 
its anionic groups (Fig. S9). 
Diclofenac, meclofenamic acid and TNS also share similarities with respect to their binding 
pose: the negatively charged moieties make salt bridges with Lys10, while their aromatic ring is 
close to the Phe6 residue (Fig. 7, Fig. S10 and S11). 
In case of ibuprofen, salt bridges between the carboxylate group and Lys15/Arg19 residues 
stabilize the binding (Fig. S12). Besides the salt bridge between the carboxyl group and the 
Lys12, the hydroxyl and amide functions of glychocolate establish four H-bonds with Glu16 and 
Lys8 (Fig. S13). 
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The energy- and population-based analysis of the binding sites suggests the importance of 
electrostatic interactions between negatively charged groups of the compounds and basic 
residues of LL-37. The results underline the significance of the “lysine core” (Lys8, Lys10, 
Lys12, Lys15, Lys18) and proximal arginines (Arg7, Arg19), especially when considering other 
clusters as well (Fig. S14). Therefore, it can be assumed that the peptide folding is mediated by 
multiple insertion of the anionic ligand molecules among the adjacent cationic side chains 
decreasing the repulsive ionic forces between them and thus allowing helix formation (Fig. 8). 
This mechanism is especially favoured for ligands owing negative charge at both ends such as 
suramin, tartrazine, olsalazine, etc. (Scheme 2).  
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Conclusions 
 
The CD spectroscopic data presented herein unveil the pronounced impact of a chemically 
diverse set of small molecules on the secondary structure of LL-37. Governed by electrostatic 
and hydrophobic ligand-side chain interactions, these agents induce disorder-to-helix 
conformational transition or significantly increase the helical content of the peptide folded 
partially at physiological chloride concentration. Results from docking of selected compounds to 
the helical structure of LL-37 gave useful information about molecular details of the binding and 
provide a potential structural explanation of the fold-inducing effect of antiinflammatory drugs 
and food dyes. Despite of well-known boundaries, molecular docking methods are potentially 
susceptible to screen fold-inducing ability of additional molecules on LL-37 and other 
antimicrobial peptides. Since the mechanism of action of LL-37 is strongly conformation-
dependent, our results suggest that these folding inducers may affect the biological activities of 
the peptide. Food dyes as well as antiinflammatory drugs used routinely in the clinical practice 
may perturb LL-37 mediated pathways especially in the gastrointestinal tract with currently 
unknown outcomes. Similarly, certain metabolic products including hemin, bile pigments and 
bile salts may act as the endogenous regulators of LL-37 both under normal and pathological 
conditions. These findings also envisage the general possibility of structural impact of anionic 
small molecules on disordered peptide/protein sequences enriched in cationic residues. It is 
hoped that these results will help to understand better the pharmacological effects of drugs as 
well as the regulatory roles of metabolites and propel the development of novel therapeutics for 
devastating infectious, inflammatory and malignant disorders. 
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Ligand      Kd (M)       h R
2
 
Hemin 20.0 (±1.5)
h
 
36.3 (±3.3)
*
 
1.8 (±0.2)
h
 
1.5 (±0.1)
*
 
0.9954
h
 
0.9971
*
 
Bilirubin 
ditaurate 
11.4 (±0.8)
h 
18.4 (±1.8)
*
 
1.7 (±0.1)
h 
1.7 (±0.2)
*
 
0.9990
h
 
0.9969
*
 
Stercobilin 135 (±13)
h 
– 
2.0 (±0.2)
h 
– 
0.9974
h
 
     – 
Suramin 2.0 (±0.1)
h 
4.9 (±0.5)
*
 
3.1 (±0.2)
h 
1.8 (±0.1)
*
 
0.9984
h
 
0.9971
*
 
Olsalazine 16.2 (±0.5)
h 
16.2 (±0.5)
*
 
2.3 (±0.1)
h 
1.9 (±0.1)
*
 
0.9976
h
 
0.9984
*
 
Balsalazide 52.6 (±0.8)
h 
54.1 (±0.7)
*
 
2.6 (±0.1)
h 
2.6 (±0.1)
*
 
0.9990
h
 
0.9993
*
 
Sulfasalazine 46.6 (±5.9)
h 
57.5 (±2.8)
*
 
1.9 (±0.2)
h 
2.5 (±0.2)
*
 
0.9964
h
 
0.9973
*
 
Diclofenac 83.0 (±4.7)
h 
86.2 (±2.8)
*
 
2.4 (±0.2)
h 
2.4 (±0.1)
*
 
0.9909
h
 
0.9961
*
 
Meclofenamic 
acid 
39.2 (±1.5)
h 
48.5 (±1.8)
*
 
3.8 (±0.3)
h 
2.6 (±0.2)
*
 
0.9955
h
 
0.9972
*
 
(±)-Ibuprofen 485 (±48)
h 
476 (±51)
*
 
2.0 (±0.1)
h 
2.1 (±0.1)
*
 
0.9983
h
 
0.9977
*
 
Cromolyn 282 (±66)
h 
224 (±49)
*
 
1 (±0.1)
h 
1 (±0.1)
*
 
0.9898
h
 
0.9862
*
 
Taurocholate  – 
273 (±18)
*
 
– 
2.3 (±0.2)
*
 
     – 
0.9975
*
 
Glycocholate 238 (±16)
h 
237 (±24)
*
 
1.7 (±0.1)
h 
1.5 (±0.1)
*
 
0.9983
h
 
0.9958
*
 
Allura red AC 6.0 (±0.3)
h
 
15.5 (±1.4)
*
 
2.2 (±0.2)
h
 
2.3 (±0.2)
*
 
0.9957
h
 
0.9934
*
 
Tartrazine 11.7 (±0.6)
h
 
14.7 (±2.6)
*
 
2.7 (±0.2)
h
 
1.7 (±0.2)
*
 
0.9978
h
 
0.9912
*
 
TNS 61.3 (±1.5)
h
 
60.1 (±1.0)
*
 
3.0 (±0.2)
h
 
3.7 (±0.2)
*
 
0.9982
h
 
0.9978
*
 
Table 1. 
LL-37 binding parameters (Kd and the Hill coefficient) of folding inducer agents estimated from non-linear 
regression analysis of the changes of the helical content
h
 (%) and the CD extremum
*
 of the n-* band ( in mdeg 
measured between 222-226 nm). Experimental data were acquired in 10 mM Tris-HCl buffer at pH 7.4. No reliable 
fit could be obtained for the  values and the helical content of stercobilin and taurocholate, respectively.  
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Ligand      Kd (M)       h R
2
 
Olsalazine 26.7 (±1.4) 1.9 (±0.1) 0.9949 
Balsalazide 160 (±25) 1.8 (±0.2) 0.9967 
Diclofenac 97.3 (±12) 1.7 (±0.2) 0.9937 
Meclofenamic 
acid 
70.5 (±7.3) 1.3 (±0.1) 0.9931 
Tartrazine 35.1 (±3.6) 2.0 (±0.1) 0.9985 
 
 
Table 2. 
LL-37 binding parameters of some folding inducers at physiological chloride level estimated 
from non-linear regression analysis of the increase of n-* CD band ( in mdeg measured 
between 222-224 nm). CD spectroscopic data were acquired in 10 mM Tris-HCl buffer 
containing 130 mM NaCl (pH 7.4). 
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Name Q    / Å
2
       
          / 
(kcal/mol) 
  
     / 
M 
Clust. No. f        
  / (kcal/ 
mol) 
Olsalazine -2 270.17±0.12 18 -5.20±0.02 176±6 1. 0.329 -5.28±0.03 
2. 0.328 -5.28±0.02 
3. 0.137 -5.30±0.03 
Balsalazide -2 337.55±0.19 34 -4.64±0.03 525±27 1. 0.313 -4.95±0.05 
2. 0.213 -4.45±0.04 
3. 0.133 -4.63±0.06 
Sulfasalazine -2 349.32±0.31 16 -4.59±0.04 495±16 1. 0.369 -4.83±0.03 
2. 0.310 -4.35±0.02 
3. 0.159 -4.60±0.04 
Diclofenac -1 255.37±0.07 16 -4.42±0.02 656±22 1. 0.530 -4.66±0.01 
2. 0.248 -4.22±0.01 
3. 0.049 -4.07±0.03 
Meclofenamic 
acid 
-1 259.33±0.04 11 -4.65±0.01 410±9 1. 0.886 -4.70±0.007 
2. 0.045 -4.26±0.01 
3. 0.033 -4.25±0.03 
Ibuprofen -1 240.00±0.15 11 -4.91±0.01 264±5 1. 0.395 -4.90±0.01 
2. 0.381 -4.98±0.02 
3. 0.084 -4.90±0.02 
Glycocholate -1 403.20±0.61 89 -4.41±0.05 1124±88 1. 0.091 -5.69±0.19 
2. 0.065 -4.53±0.10 
3. 0.064 -4.83±0.11 
Tartrazine -3 386.09±0.14 15 -5.27±0.03 194±10 1. 0.323 -5.75±0.03 
2. 0.186 -5.47±0.03 
3. 0.162 -5.09±0.02 
TNS -1 303.57±0.04 10 -4.22±0.01 829±11 1. 0.550 -4.23±0.01 
2. 0.192 -4.15±0.003 
3. 0.102 -4.25±0.02 
 
Table 3. 
Docking results of the selected molecules. Molecular properties (charge at pH 7.4 (Q), surface 
area (  ), average binding free energies (       ), average inhibitory constants (   
    ) and 
results of clustering (total number of clusters (      
 ), fraction of the clusters (f), binding free 
energy of the clusters        
 ) are shown. The 95% confidence intervals was calculated using t-
distribution. 
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Scheme 1. 
The amino acid sequence and helix-wheel representation of the human LL-37. 
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Scheme 2. 
The chemical structure of small molecules used in this study.  
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Figure 1. Representative far-UV CD spectroscopic changes of LL-37 (18 M) measured upon 
consecutive addition of various organic compounds into the sample solution (10 mM Tris-HCl 
buffer at pH 7.4). Arrows denote isosbestic points around 205-207 nm.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
25 
 
 
 
Figure 2. 
Selected examples for changes of the helix content of LL-37 elicited by various small molecules. 
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Figure 3. 
Maximum helix content of LL-37 (18 M) induced by a variety of small molecules. 
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Figure 4. 
Effect of small molecules on the far-UV CD spectrum of LL-37 (10 M) measured in 10 mM 
Tris-HCl buffer containing 130 mM sodium chloride (pH 7.4).  
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Figure 5. 
Comparison of the experimental (Table 1, helical content) and computed (Table 3) Kd values of 
various ligands on LL-37. TRT: tartrazine; OLS: olsalazine; MCL: meclofenamic acid; SLF: 
sulfasalazine; BLS: balsalazide; TNS: 2-(p-toluidino)-6-naphthalenesulfonic acid; DCL: 
diclofenac; GLC: glycocholate; IBP: ibuprofen. 
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Figure 6. 
Preferred binding site of tartrazine on LL-37. H atoms bonded to C atoms are not shown. Green: 
carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: oxygen; yellow: 
sulfur. Dashed lines show ligand-residue salt bridges. 
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Figure 7. 
Preferred binding site of diclofenac on LL-37. H atoms bonded to C atoms are not shown. Green: 
carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: oxygen; yellow: 
sulfur. Dashed lines show salt bridges between Lys10 and the ligand molecule. 
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Figure 8. 
A multiple binding mode of olsalazine molecules on LL-37 based on representatives of other 
clusters. H atoms bonded to C atoms are not shown. Green: carbon (ligand); cyan: carbon (LL-
37); white: hydrogen; blue: nitrogen; red: oxygen; yellow: sulfur. 
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Highlights 
 
 Ligand binding induced helical folding of the immunomodulatory and host-defense 
peptide LL-37 is demonstrated. 
 Its rapid, disorder-to-order conformational conversion is provoked by chemically diverse, 
synthetic and natural organic compounds including antiinflammatory drugs, porphyrin 
pigments, bile salts and food dyes. 
 Cooperative accommodation of the ligand molecules to the Lys8-Arg19 segment of the 
peptide results in multimeric complexes stabilized mainly by ionic interactions. 
 These findings could be of interest both in drug pharmacology and to understand the 
pleiotropic biological functions of LL-37. 
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Supplementary Tables 
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 Surface area / Å2 
Total no. of 
clusters 
Avg. energy 
/ (kcal/mol) ������/ �M ������/ �M ������	/ �M 
Surface area / 
Ǻ2 1.00 0.48 0.15 0.27 -0.28 -0.27 
Total number 
of clusters 0.48 1.00 0.05 0.18 0.03 -0.02 
Avg. energy / 
(kcal/mol) 0.15 0.05 1.00 0.95 0.58 0.60 ������/ �M 0.27 0.18 0.95 1.00 0.62 0.60 ������/ �M -0.28 0.03 0.58 0.62 1.00 0.98 ������/ �M -0.27 -0.02 0.60 0.60 0.98 1.00 
 
 
Table S1. 
Correlation table of Spearman’s correlation coefficients for experimental and calculated 
properties. Based on all docked molecules. 
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 Surface area / Å2 
Total no. of 
clusters 
Avg. energy / 
(kcal/mol) ������/ �M ������/ �M ������/ �M 
Surface 
area / Å2 1.00 0.37 0.02 0.19 0.02 0.05 
Total 
number of 
clusters 
0.37 1.00 0.01 0.17 0.32 0.26 
Average 
energy / 
(kcal/mol) 
0.02 0.01 1.00 0.93 0.90 0.93 ������/ �M 0.19 0.17 0.93 1.00 0.95 0.93 ������/ �M 0.02 0.32 0.90 0.95 1.00 0.98 ������/ �M 0.05 0.26 0.93 0.93 0.98 1.00 
 
 
Table S2. 
Correlation table of Spearman’s correlation coefficients for experimental and calculated 
properties. Based on the docked molecules excluding ibuprofen. 
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Figure S1. 
The  dependence of total average RMSD values on the numbers of pure CD components 
obtained by the CCA+ analysis.  
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Figure S2. 
Two types of the pure-component CD spectra sets as a result of the CCA+ analysis of CD 
titration curves of LL-37. 
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Figure S3. 
Top panel: selected far-UV CD spectra of 18 �M LL-37 measured upon consecutive increase 
of TNS concentration in the sample solution (10 mM Tris-HCl buffer at pH 7.4). 
Bottom panel: helix contents obtained from the CD titration data. Solid line is the result of 
non-linear curve tting analysis performed by using the “One site - specific binding with Hill 
slope” equation built in the Graph Pad Prism software (ver. 6.01, San Diego, California, 
USA). Kd value and the Hill coefficient (h) are shown. 
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Figure S4. 
Effect of imatinib on the far-UV CD spectrum of 18 �M LL-37 (10 mM Tris-HCl buffer at 
pH 7.4). 
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Figure S5. 
Top panel: selected far-UV CD spectra of 18 �M LL-37 measured upon consecutive increase 
of sodium chloride concentration of the sample solution (10 mM Tris-HCl buffer at pH 7.4). 
Bottom panel: helix contents obtained from the CD titration data. Solid line is the result of 
non-linear curve tting analysis performed by using the “One site - specific binding with Hill 
slope” equation built in the Graph Pad Prism software (ver. 6.01, San Diego, California, 
USA). Kd value and the Hill coefficient (h) are shown.  
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Figure S6. 
Effect of porphyrin pigments and suramin on the far-UV CD spectrum of LL-37 (10 �M) 
measured in 10 mM Tris-HCl buffer containing 130 mM sodium chloride (pH 7.4). 
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Figure S7. 
The preferred binding site of sulfasalazine on LL-37. H atoms bonded to C atoms are not 
shown. Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: 
oxygen; yellow: sulfur. Dashed lines show ligand-residue salt bridges and two H-bonds with 
Lys18. 
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Figure S8. 
The preferred binding site of balsalazide on LL-37. H atoms bonded to C atoms are not 
shown. Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: 
oxygen; yellow: sulfur. Dashed lines show ligand-residue salt bridges. 
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Figure S9. 
The preferred binding site of olsalazine on LL-37. H atoms bonded to C atoms are not shown. 
Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: oxygen; 
yellow: sulfur. Dashed lines show ligand-residue salt bridges and H-bonds (Lys10---OH–). 
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Figure S10. 
The preferred binding site of meclofenamic acid on LL-37. H atoms bonded to C atoms are 
not shown. Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; 
red: oxygen; yellow: sulfur. Dashed lines show ligand-residue salt bridges. 
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Figure S11. 
The preferred binding site of TNS on LL-37. H atoms bonded to C atoms are not shown. 
Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: oxygen; 
yellow: sulfur. Dashed lines show ligand-residue salt bridges and H-bonds (Ser9---HN<). 
 
 
  
 
12 
 
 
 
 
 
 
Figure S12. 
The preferred binding site of S-ibuprofen on LL-37. H atoms bonded to C atoms are not 
shown. Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: 
oxygen; yellow: sulfur. Dashed lines show ligand-residue salt bridges. 
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Figure S13. 
The preferred binding site of glycocholic acid on LL-37. H atoms bonded to C atoms are not 
shown. Green: carbon (ligand); cyan: carbon (LL-37); white: hydrogen; blue: nitrogen; red: 
oxygen; yellow: sulfur. Dashed lines show ligand-residue salt bridges and H-bonds. 
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Figure S14. 
The binding site of tartrazine on LL-37 based on cluster 3 (see Table 3 in the main text). H 
atoms bonded to C atoms are not shown. Green: carbon (ligand); cyan: carbon (LL-37); white: 
hydrogen; blue: nitrogen; red: oxygen; yellow: sulfur. Dashed lines show ligand-residue salt 
bridges. 
